Altamira Therapeutics Ltd. CYTOF
0.07
0.00
0.00%
as of 24 Sep
- Market cap
- $1.1M
- P/E
- 0.0×
Follow CYTOF
| Older periods | Jun '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
0.00 | 0.00 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(25.39) | (6.27) | — | — | |
P/B ratio |
18.75 | 0.00 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
0.00 | 0.00 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(6.37) | (1.94) | — | — | |
EV/FCF |
(5.17) | (1.63) | — | — | |
Quick Ratio |
0.10 | 0.20 | 0.37 | 0.09 | |
Current Ratio |
0.20 | 0.32 | 0.43 | 0.11 | |
Net Debt/EBITDA |
(0.62) | (0.60) | 0.00 | 0.00 | |
Debt/Assets |
28.25% | 49.34% | 0.00% | 6.04% | |
Debt/Equity |
0.68 | (1.68) | 0.00 | 0.11 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 1.44 | 0.00 | 0.00 | |
Capex/Depreciation |
(25.25) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Intangible Assets out of Total Assets |
0.86 | 0.63 | 0.57 | 0.65 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.06) | (0.13) | — | — | |
Graham Number |
0.00 | 20.88 | — | — | |
Earnings Yield |
(28.36%) | (312.71%) | — | — | |
Free Cash Flow Yield |
(19.98%) | (65.00%) | — | — | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
(7.64) | (2.04) | 0.00 | 0.00 | |
Capex per Share |
(2.05) | 0.00 | — | — | |
Free Cash Flow per Share |
(9.69) | (2.04) | 0.00 | 0.00 | |
Cash per Share |
0.50 | 0.08 | 0.00 | 0.00 | |
Shareholders Equity per Share |
10.35 | (0.48) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
10.35 | (0.48) | 0.00 | 0.00 | |
Free Cash Flow |
(7.51) | (8.58) | (3.20) | (1.38) | |
Working Capital |
(8.21) | (4.05) | (0.70) | (2.06) | |
Capital Expenditures |
(1.59) | — | — | — | |
Net Current Asset Value |
(9.27) | (7.01) | (1.23) | (2.81) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.41 | 0.48 | 0.14 | 0.62 | |
Average Payables |
2.07 | 1.74 | 1.06 | 2.33 | |
Average Assets |
13.85 | 15.22 | 16.87 | 13.90 | |
Average Common Equity |
6.37 | 8.47 | 14.02 | 9.01 |
Columns are period end dates